207798-38-7

Basic information

• Product Name: 4-(4-FORMYL-PHENOXY)-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER
• Synonyms: 4-(4-FORMYL-PHENOXY)-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER;tert-butyl 4-(4-forMylphenoxy)piperidine-1-carboxylate
• CAS NO: 207798-38-7
• Molecular Formula: C₁₇H₂₃NO₄
• Molecular Weight: 305.36900
• Mol File: 207798-38-7.mol
• Article Data: 17

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-(4-FORMYL-PHENOXY)-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-FORMYL-PHENOXY)-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(207798-38-7)
• EPA Substance Registry System: 4-(4-FORMYL-PHENOXY)-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(207798-38-7)

Safety Data

• Hazardous Substances Data: 207798-38-7(Hazardous Substances Data)

Usage

General Description

The chemical 4-(4-Formyl-phenoxy)-piperidine-1-carboxylic acid tert-butyl ester is a compound with a molecular formula of C18H23NO5. It is typically used as a building block in organic synthesis and pharmaceutical research. The tert-butyl ester group allows for increased stability and solubility of the compound, making it useful for various applications in the chemistry and pharmaceutical industries. This chemical may have potential uses in drug development and can serve as a precursor for the synthesis of various bioactive molecules.

Upstream product

• 10465-78-8 diamide 
• 123-08-0 4-hydroxy-benzaldehyde 
• 109384-19-2 t-butyl 4-hydroxy piperidine-1-carboxylate 
• 4143-61-7 diethyl diazodicarboxylate 
• 118811-07-7 tert-butyl 4-(tosyloxy)piperidin-1-carboxylate 
• 141699-59-4 1-(tert-butoxycarbonyl)piperidin-4-yl methanesulfonate 

Downstream Products

• 1190979-26-0 N-tert-butyl 4-(4-((4-(methylsulfonyl)piperazin-1-yl)methyl)phenoxy)piperidine-1-carboxylate 
• 1404097-23-9 4-(1-nicotinoylpiperidin-4-yloxy)benzaldehyde 
• 1404097-22-8 4-(1-picolinoylpiperidin-4-yloxy)benzaldehyde 
• 1404097-26-2 4-(1-(5-chloropicolinoyl)piperidin-4-yloxy)benzaldehyde 
• 1404097-28-4 4-(1-(3-(trifluoromethyl)benzoyl)piperidin-4-yloxy)benzaldehyde 
• 1404097-29-5 4-(1-(3-fluoro-4-(trifluoromethyl)benzoyl)piperidin-4-yloxy)benzaldehyde 
• 1404097-30-8 4-(1-(4-(difluoromethoxy)benzoyl)piperidin-4-yloxy)benzaldehyde 
• 1404097-25-1 4-(1-(2-chloronicotinoyl)piperidin-4-yloxy)benzaldehyde 
• 1404097-31-9 4-(1-(4-nitropyridin-2-yl)piperidin-4-yloxy)benzaldehyde 
• 1404097-32-0 4-(1-(5-nitropyridin-2-yl)piperidin-4-yloxy)benzaldehyde 
• 1404097-33-1 2-(4-(4-formylphenoxy)piperidin-1-yl)nicotinonitrile 
• 1404097-34-2 4-(1-(3-(trifluoromethyl)pyridin-2-yl)piperidin-4-yloxy)benzaldehyde 
• 1404097-48-8 4-(1-(5-methylpyrazine-2-carbonyl)piperidin-4-yloxy)benzaldehyde 
• 1404097-49-9 4-(1-(4-chloro-2-methoxybenzoyl)piperidin-4-yloxy)benzaldehyde 

Relevant articles and documents

8-substituted styryl xanthine derivative and application thereof

The invention discloses an 8-substituted styryl xanthine derivative and application thereof, and particularly relates to a novel 8-substituted styryl xanthine derivative and a pharmaceutical composition containing the compound which can be used as a selective adenosine A2A receptor antagonist. The invention also relates to a method for preparing the compound and the pharmaceutical composition, andapplication of the compound and the pharmaceutical composition in preparation of drugs for treating adenosine A2A receptor related diseases, especially Parkinson's disease.

Tetrahydroquinoline derivative as well as preparation method and application thereof

The invention belongs to the field of drug synthesis, and provides a tetrahydroquinoline derivative shown as a general formula (I) and pharmaceutically acceptable salt, stereoisomers or prodrugs thereof, in which A, Ra, Rb, n, m and R are as described in

Thieno[3,2-b]pyrrole-5-carboxamides as New Reversible Inhibitors of Histone Lysine Demethylase KDM1A/LSD1. Part 2: Structure-Based Drug Design and Structure-Activity Relationship

The balance of methylation levels at histone H3 lysine 4 (H3K4) is regulated by KDM1A (LSD1). KDM1A is overexpressed in several tumor types, thus representing an emerging target for the development of novel cancer therapeutics. We have previously describe